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Abstract
Hypoxanthine phosphoribosyltransferases (HPRTs) are of biomedical interest because defects in the enzyme from humans
can result in gouty arthritis or Lesch^Nyhan syndrome, and in parasites these enzymes are potential targets for antiparasite
chemotherapy. In HPRTs, a long flexible loop (active site loop II) closes over the active site during the enzyme catalyzed
reaction. Functional roles for this loop have been proposed but have yet to be substantiated. For the present study, seven
amino acids were deleted from loop II of the HPRT from Trypanosoma cruzi to probe the functional role of this active site
loop in catalysis. The mutant enzyme (vloop II) was expressed in bacteria, purified by affinity chromatography, and kinetic
constants were determined for substrates of both forward (purine salvage) and reverse (pyrophosphorolysis) reactions
catalyzed by the enzyme. Loop II deletion resulted in moderate (0.6^2.7-fold) changes in the Michaelis constants (Kms) for
substrates other than pyrophosphate (PPi), for which there was a 5.8-fold increase. In contrast, kcat values were severely
affected by loop deletion, with rates that were 240^840-fold below those for the wild-type enzyme. Together with previously
reported structural data, these results are consistent with active site loop II participating in transition-state stabilization by
precise positioning of the substrates for in line nucleophilic attack and in the liberation of PPi as a product of the salvage
reaction. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Hypoxanthine phosphoribosyltransferases
(HPRTs; inosine monophosphate:pyro-phosphate
phosphoribosyltransferase, EC 2.4.2.8) are enzymes
involved in the recycling of preformed purine bases
from degraded nucleotides. These enzymes catalyze
the Mg2-dependent reversible transfer of a phos-
phoribosyl group from 5-phospho-K-D-ribosyl-1-py-
rophosphate (PRPP) to the imidazole N9 position
of 6-oxopurines to form a ribonucleoside monophos-
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phate and inorganic pyrophosphate (PPi). HPRTs
have been proposed as possible targets for chemo-
therapeutic agents in the treatment of diseases caused
by parasites [1], including Trypanosoma cruzi, etio-
logic agent of Chagas’ disease [2]. Also, partial to
complete absence of HPRT activity in humans is
associated with heritable gouty arthritis and Lesch^
Nyhan syndrome [3].
For those enzymes which have been studied, the
HPRT-catalyzed reaction has been reported to be
ordered and sequential, with PRPP binding before
the purine base and PPi being released prior to the
ribonucleotide [4^6]. Both SN1- and SN2-type reac-
tion chemistries have been proposed [7]. An associa-
tive, SN2 mechanism would proceed through nucleo-
philic attack by the purine N9 on the anomeric C1P-
carbon of PRPP in concert with pyrophosphate re-
lease [8,9]. A two-step, SN1-type chemical mechanism
would involve a charged ribooxocarbenium inter-
mediate that forms either after the dissociation of
PPi from PRPP in the forward salvage reaction, or
after the dissociation of the purine base from a nu-
cleotide in the reverse pyrophosphorolysis reaction
[10^12].
Disorder in the electron density for atoms in active
site loop II in early X-ray crystal structures of
HPRTs made accurate modeling di⁄cult and indi-
cated that loop II might be relatively £exible. These
observations led to a proposed function for loop II
in sequestering the active site chemistry from bulk
solvent during the transition-state [11,13,14]. Recent
crystal structures of trypanosomal [8], human [15,16],
and malarial [17] HPRTs con¢rm that loop II closes
over bound substrates and substrate analogs as the
enzyme approaches the transition-state of either the
forward or reverse reaction. Furthermore, the closed
structures of all three HPRTs reveal key interactions
of loop II residues with bound substrates and metal-
coordinated water molecules. The majority of these
interactions occur with main chain atoms of loop II
residues. Hydrogen bond interactions between the
closed loop and PPi oxygens and metal-coordinated
waters were proposed to provide a possible mecha-
nism for the liberation of the PPi leaving group in
the purine salvage reaction [8]. These interactions
include hydrogen bonds between the main chain ni-
trogens of Ser81 and Tyr82 (human Ser103 and
Tyr104) and O1A of PRPP or PPi. In addition, the
Tyr82 side chain hydroxyl forms a hydrogen bond
with a 5P-phosphate oxygen of either PRPP or a nu-
cleotide analog. These hydrogen bonds position the
aromatic ring of Tyr82 nearly perpendicular to the
ribose ring of PRPP or the nucleotide analog just
above the reactive site. The importance of the Ser^
Tyr dipeptide in catalysis is emphasized both by its
conservation among 6-oxopurine phosphoribosyl-
transferases [18] and by the results of site-directed
mutations of these residues [19,20], but details of
structure^function relationships for these amino
acids remain poorly understood.
In order to explore the functional role for loop II
in the HPRT of T. cruzi, a loop II deletion mutant
(vloop II) was engineered using overlap extension
PCR [21]. The e¡ects of loop II deletion on the
HPRT-catalyzed reaction were evaluated by analyses
of apparent steady-state kinetic parameters for hypo-
xanthine, guanine, and PRPP in the forward reaction
and for inosine monophosphate (IMP) and PPi in the
reverse reaction catalyzed by the mutant enzyme.
The results of these studies suggest that active site
loop II plays roles both in positioning and stabilizing
substrates in the transition-state and in liberating as
well as binding PPi.
2. Materials and methods
2.1. Materials
MAX E⁄ciency DH5K competent Escherichia coli
were from Life Technologies (Gaithersburg, MD).
The recA3 strain of the E. coli SP606 (F3ara,
vpro-gpt-lac, thi, hpt) [22] host for recombinant
HPRT expression was provided by Duncan Cochran
(University of Queensland, Australia). Synthetic oli-
gonucleotides were from Gibco BRL (Gaithersburg,
MD). Restriction endonucleases were purchased
from New England BioLabs (Beverly, MA). Ampli-
Taq Gold thermostable DNA Polymerase was ob-
tained from Perkin Elmer (Norwalk, CT).
The [8-14C]hypoxanthine (47.1 Ci/mol) and [8-14C]-
IMP (55 Ci/mol) used in radiochemical enzyme
assays were from Moravek Biochemicals (Brea, CA).
The [K-35S]dATP for sequencing was from ICN
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(Costa Mesa, CA). Xanthine oxidase (20 U/ml) was
from Boehringer Mannheim (Indianapolis, IN).
GMP-agarose, unlabeled hypoxanthine, guanine,
PRPP, PPi and PEI-cellulose were from Sigma
Chemical Co. (St. Louis, MO).
2.2. Construction of the loop deletion (vloop II)
mutant of the HPRT from T. cruzi
PCR deletion mutagenesis was performed by the
method of overlap extension [21]. For this purpose,
overlapping oligonucleotide primers (5P-ATG GAA
TTC ATT TGC GTC TCA TCA TCC GGT CAG
GTT CGA ATG TTG CTT G-3P and 5P-AAG CAA
CAT TCG AAC CTG ACC GGA TGA TGA GAC
TCA AAT GAA TTC CAT TCG-3P) were designed
to delete amino acid residues 82^88 (-YGEGLTS-) in
loop II of the T. cruzi HPRT. For diagnostic pur-
poses, and to facilitate future studies, silent muta-
tions were included in the oligonucleotide primers
to create restriction sites for EcoRI (GAATTC)
and BstBI (TTCGAA) (underlined above). An ex-
pression construct containing DNA encoding the
wild-type HPRT from T. cruzi [23] was used as the
template for PCR mutagenesis. DNA sequencing, us-
ing dideoxy chain termination methods [24] con-
¢rmed the deletion of the seven amino acids from
active site loop II.
2.3. Recombinant expression and puri¢cation of the
vloop II mutant
The recombinant vloop II mutant enzyme was ex-
pressed at high levels and puri¢ed to near homoge-
neity from the soluble supernatant by GMP-agarose
a⁄nity chromatography as described [23]. Protein
was quanti¢ed by the Bradford method using IgG
as the protein standard in the Bio-Rad Protein Assay
kit (Hercules, CA).
2.4. Radiochemical analysis of the forward reaction
catalyzed by the vloop II mutant
HPRT activity for the forward reaction was ini-
tially measured by radiochemical assay as described
[25]. Puri¢ed, desalted, recombinant enzyme was
used in the assays. Twenty WM of [8-14C]-radiola-
beled hypoxanthine was used in forward reaction
assays and the total concentration of hypoxanthine
was adjusted as needed by the addition of non-radio-
active hypoxanthine. Substrate hypoxanthine and
product IMP were resolved by polyethyleneimine
(PEI) cellulose anion-exchange thin-layer chromatog-
raphy, and radioactivity was assayed by scintillation
spectrometry as described [25].
To con¢rm that the only product formed with ra-
dioactive hypoxanthine was IMP, the vloop II en-
zyme (3 Wg) was incubated at 37‡C for 7.5 min
with 100 WM hypoxanthine (20 WM ‘hot’+80 WM
unlabeled hypoxanthine) and 800 WM PRPP. Subse-
quently, the substrate and products were resolved by
two-dimensional (2-D) PEI-cellulose chromatogra-
phy as described [26,27], and the locations of radio-
active substrates and products were determined by
autoradiography.
2.5. Steady-state kinetic analyses of forward and
reverse reactions
A continuous spectrophotometric assay was used
for HPRT activity studies [4]. Data were collected
using a Beckman DU 640 spectrophotometer. The
formation of IMP and guanosine monophosphate
(GMP) were monitored continuously by the change
in absorbance at 245 and 257.5 nm, respectively.
IMP pyrophosphorolysis was monitored spectropho-
tometrically as described [4]. The production of hy-
poxanthine was determined indirectly by the contin-
uous spectrophotometric assay of uric acid formation
in the presence of xanthine oxidase. The formation
of uric acid was monitored by the change in absor-
bance at 293 nm. All measurements were carried out
in 100 mM Tris^HCl (pH 7.5) and 12 mM MgCl2 at
37‡C. Under these conditions, the extinction coe⁄-
cients for IMP, GMP and uric acid were 3020, 5340
and 12 000 M31 cm31, respectively. The ¢nal volume
of the assay mixture was 1 ml, containing either 200
Wg of vloop II mutant or 1 Wg of the wild-type en-
zyme, plus various concentrations of substrates. For
forward reactions, the concentrations of substrates
were varied individually over the range of 6.25^400
WM while the concentration of the second substrate
was ¢xed at 400 WM. Kinetic constants for PRPP
were determined with hypoxanthine as the second
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substrate. For reverse reactions the concentrations
for IMP and PPi were ¢xed at 500 WM while the
concentrations for the second substrate were varied
between 15^500 WM for IMP and 23^1000 WM for
PPi. Due to di¡erences in rates of forward and re-
verse reactions, purine salvage and pyrophosphorol-
ysis were monitored for 45 s and 5 min, respectively.
Apparent Km, Vmax, and kcat values were deter-
mined by non-linear regression assuming Michaelis^
Menten kinetics. Calculations were carried out using
the program ‘Enzyme Kinetics’ from Exeter Software
(Setauket, NY). Standard errors reported for Km val-
ues were derived from single experiments with 9 or
more data points.
3. Results
3.1. Expression and puri¢cation
Residues Y82GEGLTS88 of active site loop II in
the HPRT from T. cruzi were selected for deletion to
minimize perturbation of secondary or tertiary struc-
tural elements of the folded protein. The selection of
these residues was guided by the adopted conforma-
tion of loop II in the closed-loop crystal structure for
the enzyme [8]. Deletion of these residues was pre-
dicted to be possible with rejoining of the main chain
at the stem of the loop between residues Ser81 and
Ser89 (Fig. 1A). Modeling of the vloop II mutant
suggests that deletion of the loop leaves the HPRT
active site fully accessible to bulk solvent (Fig. 1B).
The vloop II mutation was engineered and the
mutant enzyme expressed in E. coli SÒ606 using
the pBAce expression vector [28]. Using this system,
soluble puri¢ed enzyme was obtained by GMP-aga-
rose a⁄nity chromatography. As seen in Fig. 2, the
mutant enzyme bound GMP-agarose, indicating that
removal of the loop II residues did not adversely
a¡ect the overall fold of the protein or the integrity
of the active site.
C
Fig. 1. Amino acids for deletion of loop II in HPRTs were se-
lected based on the structure of the closed active site. (A) An
K-carbon trace (in blue) of the closed subunit of the ternary
complex structure of the HPRT from T. cruzi illustrating the
adopted conformation of active site loop II [8]. The loop II re-
gion selected for deletion mutagenesis is indicated in yellow.
The purine analog and PRPP ligands are displayed as stick
models in standard atom coloring. The side chains for Ser81
and Ser89 are shown £anking the deleted region. The ¢gure
was drawn with the program SETOR [31]. (B) Representations
of the surface electrostatic potentials of the closed subunit (at
left) and of a model of the predicted structure of the vloop II
mutant HPRT (at right). Negatively and positively charged re-
gions of the protein are colored red and blue, respectively.
These representations were created using the program GRASP
[32]. The purine analog and PRPP ligands are displayed as stick
¢gures with standard atom coloring.
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3.2. Kinetic analysis of purine salvage reactions
catalyzed by the vloop II HPRT
The apparent steady-state kinetic parameters for
hypoxanthine, guanine, and PRPP were determined
for the recombinant vloop II HPRT (Table 1) and
compared to values determined for the recombinant
wild-type enzyme. For the vloop II mutant, the kcats
with variable concentrations of hypoxanthine and
guanine were 380- and 840-fold, respectively, below
those for the wild-type enzyme (Table 1). The kcat
with variable [PRPP] was about 460-fold below that
for the wild-type enzyme (Table 1). The overall cata-
lytic e⁄ciencies (kcat/Kms) with hypoxanthine, gua-
nine, and PRPP for the vloop II enzyme were
roughly 1000-, 950-, and 290-fold, respectively, below
the values with the wild-type enzyme (Table 1). The
Kms for substrates PRPP and guanine were largely
una¡ected by the deletion of active site loop II and
the Km for hypoxanthine was only V2.7-fold higher
than that for the wild-type enzyme. Thus, the large
reductions in catalytic e⁄ciencies of forward reac-
tions catalyzed by the vloop II mutant were due
largely to decreases in kcat.
3.3. The e⁄cient salvage of hypoxanthine by the
vloop II mutant HPRT
In order to show that all of the purine base sal-
vaged by the vloop II mutant was accounted for in
the product IMP, 2-D anion-exchange thin-layer
chromatography on PEI-cellulose was employed to
separate the substrate and product from radiochem-
ical enzyme reactions [26,27]. The reactions were
chromatographed with distilled water in the ¢rst di-
mension and 1.6 M LiCl in the second dimension.
Autoradiograms of these PEI-cellulose sheets demon-
strated that input radioactivity was accounted for
entirely in either product IMP or substrate hypoxan-
thine (data not shown).
3.4. Kinetic analysis of pyrophosphorolysis reactions
catalyzed by the vloop II HPRT
Using the xanthine oxidase-coupled assay to re-
move the product purine base in reverse reactions,
Table 2
Apparent steady-state kinetic parameters for pyrophosphoroly-
sis reactions catalyzed by wild-type and vloop II HPRTs
Enzyme Apparent Km
(WM)
kcat
(s31)
kcat/Km
(s31 WM31)
Variable IMP
Wild-type 26.6 þ 1.52 0.471 177U1034
vLoop II 39.6 þ 3.5 0.001 0.25U1034
Variable PPi
Wild-type 34.5 þ 2.2 0.476 138U1034
vLoop II 199 þ 13 0.002 0.10U1034
Table 1
Apparent steady-state kinetic parameters for purine salvage re-
actions catalyzed by wild-type and vloop II HPRTs
Enzyme Apparent Km
(WM)
kcat
(s31)
kcat/Km
(s31 WM31)
Variable hypoxanthine
Wild-type 8.62 þ 0.97 22.9 2.66
vLoop II 23.3 þ 2.8 0.060 0.0026
Variable guanine
Wild-type 11.6 þ 1.0 32.9 2.84
vLoop II 13.2 þ 0.6 0.039 0.0030
Variable PRPP
Wild-type 32.4 þ 3.1 23.2 0.72
vLoop II 20.1 þ 1.3 0.050 0.0025
Fig. 2. The vloop II mutant HPRT was over-expressed in E.
coli and puri¢ed using a⁄nity chromatography. A Coomassie-
stained 12% polyacrylamide^sodium dodecyl sulfate gel demon-
strates the presence of the vloop II mutant HPRT in the
whole-cell lysate (Tot) and in the soluble fraction (Sol) of bac-
terial cells. The recombinant enzyme was puri¢ed to near
homogeneity as shown in ¢ve consecutive fractions from GMP-
agarose chromatography. Protein that did not bind to the col-
umn is shown in the lane marked UNB. Molecular mass stan-
dard proteins are shown in the ¢rst and last lanes of the gel,
and sizes in kDa are indicated on the right.
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steady-state kinetic parameters for IMP pyrophos-
phorolysis were determined for the vloop II mutant
and the wild-type enzyme (Table 2). The Km for IMP
was V1.5-fold higher for the vloop II mutant than
for the wild-type enzyme, but the Km for PPi was 5.8-
fold higher for the mutant than for the wild-type
enzyme (Table 2). The kcat values for pyrophosphor-
olysis by the vloop II mutant were 240- to 470-fold
below those for the wild-type enzyme under condi-
tions of variable PPi or IMP, respectively. Catalytic
e⁄ciencies for pyrophosphorolysis by the vloop II
mutant with variable IMP or PPi were 700- to
1400-fold below those for the wild-type enzyme, re-
spectively.
4. Discussion
Previous studies have supported the involvement
of residues within loop II of 6-oxopurine phosphor-
ibosyltransferases in catalysis. Studies of a bacterial
xanthine-guanine-phosphoribosyltransferase
(XGPRT) revealed that this enzyme rapidly loses
activity due to proteolysis that occurred during
puri¢cation [29]. Mass spectrometric and N-ter-
minal sequence analysis of the enzyme revealed
that the proteolysis removed 11 residues
(D66NQRELKVLKR76) in a region homologous
with active site loop II of HPRTs. The cleaved
XGPRT was observed to be catalytically inactive
but was able to bind GMP-Sepharose. The authors
suggested that the loss in catalytic activity might be
due to an inability of the loopless XGPRT to shield
the active site from bulk solvent and/or due to the
removal of positively charged loop residues that may
be essential for catalytic activity.
The crystal structure of a substrates^ternary com-
plex of the trypanosomal HPRT revealed views of
both open and closed active sites with PRPP, a pu-
rine analog, two metals and coordinated waters
bound [8]. In this structure, di¡erences between the
open and closed active sites were reported for the
positions of bound PRPP and the analog of hypo-
xanthine. The closure of loop II resulted in the sub-
strates being better positioned to facilitate hydrogen
bond formation between a proton at purine position
N7 and an active site aspartate (Asp115, homologous
with Asp137 in the human HPRT). Also, the sub-
strates were better positioned for in-line nucleophilic
attack of the purine base on the C1P atom of PRPP
[8]. An interpretation from these observations is that
loop closure is required to properly position sub-
strates, thereby contributing to stabilization of the
transition-state for the reaction.
A Ser81^Tyr82 dipeptide, located near the amino
terminus of loop II, is invariant among HPRTs [7].
Crystal structures of several HPRTs with closed ac-
tive sites [8,16,17] show that the main chain nitrogen
of the tyrosine at human position Y104 forms a hy-
drogen bond with the O1P atom of PRPP or PPi.
Also, the side-chain hydroxyl of this tyrosine forms
a hydrogen bond with the 5-phosphate of either
PRPP or the nucleotide analog in the active site.
The importance of this invariant tyrosine for enzyme
catalysis was tested by site-directed mutagenesis of
the HPRT from Leishmania donovani [19]. Mutations
of this residue to Phe or Val resulted a 2^3 order of
magnitude reduction in kcat. A comparable reduction
in kcat was observed to be the consequence of loop II
deletion in the HPRT of T. cruzi. Inspection of the
structure of the closed subunit of the HPRT from T.
cruzi [8], reveals that three atoms in the side chain of
Y82 (human Y104) are within 3.3^3.6 Aî of the 8 and
9 position atoms of the purine analog in the active
site. These structural observations suggest that dur-
ing the closure of loop II the side chain of the invar-
iant tyrosine likely has a role in orienting and posi-
tioning substrates as a contribution to decreasing the
energy barrier for a chemical reaction.
The studies reported here show that deletion of
active site loop II from the HPRT of T. cruzi does
not abolish enzymatic activity, although kcats and
catalytic e⁄ciencies were 240- to 1400-fold below
the values for the wild-type enzyme (Tables 1 and
2). Furthermore, two-dimensional chromatography
of reaction products showed that purine precursors
were converted only to nucleotides in mutant enzyme
catalyzed reactions. The relatively low activities for
forward reactions catalyzed by the vloop mutant re-
sulted largely from reductions in kcat values while the
low activity of reverse reactions resulted from both
an increase in the Km for PPi and reductions in kcat
values. Pre-steady-state kinetic and ligand binding
analyses in the human HPRT revealed that the
rate-limiting step for the enzyme-catalyzed reaction
was product release [5,30]. Although similar studies
BBADIS 62045 13-7-01 Cyaan Magenta Geel Zwart
C.C. Lee et al. / Biochimica et Biophysica Acta 1537 (2001) 63^7068
have not been reported for other HPRTs, it is likely
that the rate-limiting step will be similar for other
wild-type HPRTs. Thus, if the chemical step is not
rate limiting in the wild-type enzyme, observed kcat
values from steady-state kinetic studies of vloop II
mutant could be in£uenced by the rate of product
release as well as by the rate for the enzyme chem-
istry.
Deletion of loop II results in only 1.1^2.7-fold in-
creases in Kms for hypoxanthine, guanine, and IMP.
This result indicates that loop II is probably not in-
volved in the initial binding of either purine or nu-
cleotide substrates. The structure of the trypanoso-
mal HPRT, with substrates bound in both open and
closed conformations, show that three hydrogen
bonds between loop II residues and atoms of PRPP
are observed only in the closed loop structure [8].
Two of the hydrogen bonds are between main chain
nitrogens of Ser81 and Tyr82 and the O1P atom of
PRPP. Similar interactions also are observed in
closed structures of the human and malarial HPRTs
[16,17] where the O1P oxygen is associated with
bound PPi. An additional hydrogen bond forms be-
tween the main chain nitrogen of Ser80 (human
Ser102) and a metal coordinated water molecule.
Formerly, the hydrogen bonds with main chain
atoms in loop II of the trypanosomal HPRT were
postulated to have a role in a mechanism for liberat-
ing PPi as a product of the purine salvage reaction
[8]. The deletion of loop II from Tyr82 to Ser88
eliminates these hydrogen bond interactions. In the
vloop mutant, the Km for PPi was nearly sixfold
above that for the wild-type enzyme. This result is
consistent with loop II having a role both in binding
PPi as a substrate of the reverse pyrophosphorolysis
reaction and in liberating PPi as a product of the
salvage reaction, as predicted formerly [8].
Active site loop II has been postulated to have a
role in sequestering the active site chemistry from
bulk solvent during the transition state [11,13,14].
This hypothesis has been con¢rmed by structures of
HPRTs in closed conformations approaching the
transition state of the enzyme catalyzed reaction
[8,16,17]. The results of the present study show that
although catalytic e⁄ciencies are dramatically re-
duced, productive chemistry can occur even when
the active site is solvent accessible. The ability of
the reaction to successfully proceed even with an
active site fully exposed to solvent suggests that the
positions of bound substrates may be adequate to
prevent attack by solvent from the required direction
to hydrolyze a potentially unstable intermediate.
However, the severe loss of catalytic e⁄ciency caused
by loop deletion suggests that loop II plays a critical
role in correctly orienting the substrates and stabiliz-
ing the transition-state to promote catalysis. In sum-
mary, these results support a conclusion that the
major roles for active site loop II in HPRTs are:
(a) to provide direct interactions with PPi for binding
or product release in pyrophosphorolysis or purine
salvage reactions, respectively, and (b) to stabilize the
transition state by precisely positioning substrates for
e⁄cient chemistry.
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